TNM staging system for Renal Cell Carcinoma: current status and future perspectives Vincenzo Ficarra Dipartimento di Scienze Oncologiche e Chirurgiche.

Slides:



Advertisements
Similar presentations
Case 20 Thomas J. Giordano, M.D., Ph.D.. History A 54-year old man with a past medical history of goiter for approximately 4 years was followed by ultrasound.
Advertisements

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
Oliver Hakenberg Urologische Klinik und Poliklinik Universitätsklinikum Rostock Surgical treatment of renal cell carcinoma with caval thrombus.
 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.
Giuliano Pre-SSO mins ASCO Z mins
What is TNM? TNM is a system for classifying malignant tumours ! It is a cancer staging system, which describes the extent of a person's cancer ! Most.
Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.
59 years old man Hx of stomach adenocarcinoma 20 years ago Hx of chemoradiotherapy cc:gross hematuria.
Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Management of T1 Kidney Cancer Laparoscopic Surgery
Radiotherapy in Renal Cell Carcinoma Simin Hemati. M.D Assistant professor of Radiation Oncology Isfahan University of Medical Sciences 20 jan 2012.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.
Role of Neck Dissection for Differentiated Thyroid CA Joint Hospital Surgical Grand Round NDH Dr. Alex TSANG.
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
Risk Adapted Management of Thyroid Cancer R Michael Tuttle, MD Professor of Medicine Endocrine Service Memorial Sloan Kettering Cancer Center New York,
Linfoadenectomia e nefrectomia citoriduttiva Vincenzo Ficarra Associate Professor of Urology, University of Udine, Italy Associate Editor BJU International.
THE SIGNIFICANCE OF HISTOLOGICAL SUBSTAGING IN CURATIVE RESECTED T3 COLORECTAL CANCER Karl Mrak & Jörg Tschmelitsch Department of Surgery, Barmherzige.
Kerrington Smith, M.D. CTOS Nov 14, 2008
Cancer Staging.
강 창 현 서울대학교병원 흉부외과 서울대학교 의과대학. Staging Communication Evaluation TreatmentPrognosis Research.
Linfoadenectomia e nefrectomia citoriduttiva
Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.
Prognostic factors and predictive models Vincenzo Ficarra Associate Professor of Urology, University of Padova, Italy Scientific Director OLV Robotic Surgery.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Current Role of Partial Cystectomy: Are we scarifying patient ’ s survival Dr Eric Li Department of Surgery Pamela Youde Nethersole hospital.
Does the embolization of the tumor, prior to radical nephrectomy, prologs the life of patients with renal cell carcinoma * Department of Urology Regional.
DISCUSSION AND CONCLUSION Alberto Briganti Urological Research Institute Vita Salute San Raffaele University Dept. of Urology, Milan, Italy.
Investigation of CA9 expression in pulmonary metastatic lesions from patients with clear cell renal cell carcinoma Pierre Tennstedt 1, Peter Schneider.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
“Validation” of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients Yang Zhao; Heng Zhao Division of Thoracic.
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Radical Nephrectomy The Role Of Surgery In mRCC Peter Mulders Professor and Chairman Department of Urology University Medical Center Nijmegen The Netherlands.
Kidney Anatomical site of the kidney. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer, ©American.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Surgery As Monotherapy for Wilms’ Tumor Lisly Chéry April 15, 2010.
COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.
Maria Chiara Zatelli Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli.
The Malignant Polyp Handout Version Hans Elzinga, MD Program Director- Advanced Procedures in Family Medicine Fellowship Salud Family Health Center-Longmont,
Renal cell carcinoma : alternative treatment LUKMAN HAKIM DEPARTMENT OF UROLOGY, AIRLANGGA UNIVERSITY/DR. SOETOMO GENERAL HOSPITAL.
CLINICAL ASPECT OF GRADING AND STAGING Hanggoro Tri Rinonce, MD, PhD Department of Anatomical Pathology Faculty of Medicine, Gadjah Mada University.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Beyond breast specific—Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome Gaia Griguolo DiSCOG-University.
THE IMPORTANCE OF STAGING AND PROGNOSTIC FACTORS IN CANCER CARE
Volume 52, Issue 1, Pages (July 2007)
Lymph Node Dissection for Renal Cell Carcinoma: When, How and Why?
The IASLC Lung Cancer Staging Project The 8th Edition
Surgical Treatment in Locally Advanced Prostate Cancer
1 LINFOADENECTOMIA Alessandro Volpe Università del Piemonte Orientale
Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
MANAGEMENT OF SMALL RENAL TUMORS: Current Evidence
Neuro-Endocrine Tumoren De Appendix in het Bijzonder
TNM 8 for urological cancers An update
Staging Cancer.
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
Proposed Changes to the 7th Edition
Cancer Staging.
TNM 8 UPDATE Head and Neck SSG March 2018
SORVEGLIANZA ATTIVA DELLE PICCOLE MASSE RENALI
Volume 52, Issue 1, Pages (July 2007)
Volume 58, Issue 4, Pages (October 2010)
NSCLC: Staging and TNM classification
Presentation transcript:

TNM staging system for Renal Cell Carcinoma: current status and future perspectives Vincenzo Ficarra Dipartimento di Scienze Oncologiche e Chirurgiche Clinica di Urologia - Università degli Studi di Padova

An ideal cancer staging system should effectively: comunicate critical tumor characteristics,comunicate critical tumor characteristics, aid the clinician in the appropriate selectionaid the clinician in the appropriate selection of therapeutic options, of therapeutic options, stratify the patient’s risk of cancer progressionstratify the patient’s risk of cancer progression or cancer death and or cancer death and eventually determine the selection criteria foreventually determine the selection criteria for clinical trials clinical trials Sobin LH: TNM classification of malignant tumours; 2002 Staging systems for RCC

Flocks and Kadesky, 1958 Flocks and Kadesky, 1958 Robson, 1969 Robson, 1969 TNM, 1978 TNM, 1978 TNM, 1987 TNM, 1987 TNM, 1997 TNM, 1997 TNM, 2002 TNM, 2002 TNM, ….. ? TNM, ….. ? Staging systems for RCC

Development of the TNM staging system for localized RCC Ficarra V.et al. Eur Urol 2004; 46: YearEditionT1T2 1968UICC (I)Kidney not listed 1974UICC (II)Small tumor 1 Large tumor UICC (IV)≤ 2.5 cm> 2.5 cm 1988AJCC (III)≤ 2.5 cm> 2.5 cm 1997UICC/AJCC≤ 7 cm> 7 cm 2002UICC/AJCC≤ 4 cm (T1a)> 7 cm 4-7 cm (T1b)

TNM, 2002 Version – Why ? Hafez KS et al. J. Urol. 1999; 162: This update was mainly proposed to help the clinicians to identify patients suitable for a elective partial nephrectomy

Radical nephrectomy Vs partial nephrectomy: comparative, non randomized studies Patients with RCC  4 cm (pT1a)

Multi-Institutional European Validational of the 2002 TNM Staging System Ficarra V. et al. Cancer 2005; 104: pT1a pT1b pT2 pT1a Vs pT1b (p = ) pT1a Vs pT2 (p < ) pT1b Vs pT2 (p = ) 2,217 localized RCC 10-year CSS (%): - pT1a: 91% - pT1b: 83% - pT2: 75%

BUT … is this the best strategy to subdivide confined RCC ? Patard JJ, Ficarra V et al. J. Urol 2004; 171:

Bensalah K. et al. Eur. Urol 2008; 53: Elective Partial Nephrectomy for pT1b RCC

Anatomic features related to selection of the candidate for NSS Ficarra V et al. Eur Urol 2008 (in press) Peripheral or intraparenchymal location Spherical shape Adiacent nodular areas Tumor deepening into the kidney Relathionship with UCS

BUT … is this the best strategy to subdivide confined RCC ? Ficarra V et al. Eur. Urol 2004; 46: cm (Zisman, 2001) 5 cm (Gelb, 1993; Targaski, 1994; Igarashi,2001; Lau, 2002; Elmore, 2003; Zucchi, 2003) 5.5 cm (Kinouchi, 1999; Ficarra, 2004) Identification of different risk groups for progression or death

Proposal for Revision of the TNM 1,138 patients with a mean follow-up of 87 months after partial or radical nephrectomy 5.5 cm Ficarra V., Patard JJ et al Cancer 2005; 15: 104:

Proposal for Revision of the TNM Staging System for Renal Cell Carcinoma Ficarra V. et al Cancer 2005; 15: 104:

Prognostic Stratification of Localized Renal Cell Carcinoma by Tumor Size Bedke J. et al J Urol 2008; 180: patients with a mean follow-up of 60 months after radical or partial nephrectomy

Prognostic Stratification of Localized Renal Cell Carcinoma by Tumor Size Bedke J. et al J Urol 2008; 180: cm 7 cm

Proposal for Revision of the TNM Ficarra et al, 2005 Multicenter study (7 Centres) Retrospective 1,138 cases RN NSS Median tumor size: 5 cm IQR tumor size: 3-7 cm Median FU: 87 mo (IQR FU: mo) Martingale residuals: 5.5 cm Cut-off: 5.5 cm Bedke et al, 2008 Single Center study (?) Prospective 464 cases RN - 66 NSS Median tumor size: ? IQR tumor size: ? Median FU: 60 mo (range FU: mo) Martingale residuals: 5.5 cm Cut-off: 7 cm

Klatte T., Patard JJ, Ficarra V., et al J Urol 2007; 178: Prognostic Impact of Tumor Size on pT2 706 patients with pT2 RCC surgically treated at 9 International academic centers

Tumor Size Improves the Accuracy of TNM Predictions in patients with Renal Cancer Karakiewicz PI, Ficarra V. Patard JJ et al Eur Urol 2006; 50: Identification of an ideal breakpoint representsIdentification of an ideal breakpoint represents a complex process, wich is affected by differences a complex process, wich is affected by differences in patient characteristics in patient characteristics Spectrum bias and associated floor and ceilingSpectrum bias and associated floor and ceiling effects may be circumvented, if variables are effects may be circumvented, if variables are used without being catagorized used without being catagorized

Tumor Size Improves the Accuracy of TNM Predictions in patients with Renal Cancer Karakiewicz PI, Ficarra V. Patard JJ et al Eur Urol 2006; 50:

AJCC/UICC stage groupings cannot Incorparate countinuosly coded variables Karakiewicz PI, Ficarra V. Patard JJ et al JCO 2007; 25:

T3a Fat and adrenal inv.Fat and adrenal invasion T3b Renal vein (V1)V1 – V2 T3c IVC below diaphr (V2) V3 T4 Outside Gerota’s fascia T4a Outside Gerota’s fascia T4b IVC above diaphr (V3). TNM, 1987 TNM, 1997TNM, 2002 Development of the TNM staging system for locally advanced RCC

Ficarra V., et al. J Urol 2007; 178: ,969 locally advanced (pT3-4) RCC pT3a pT3b pT3c pT4 p value < pT3a: Fat and/or adrenal invasion pT3b: renal vein or IVC below diaphr. pT3c: IVC above diaphr. pT4: beyond Gerota Multi-Institutional European Validational of the 2002 TNM Staging System 60% 46% 12%

New staging system for pT3-4 RCC: a multicentric european study 1,117 pT3a RCC Perirenal fat Adrenal only p value = Ficarra V., et al. J Urol 2007; 178:

New staging system for pT3-4 RCC: a multicentric european study 705 pT3b RCC V1 V2 V2+fat V1-2+adrenal V1+fat p value< Ficarra V., et al. J Urol 2007; 178:

Reclassification of patients with pT3 and pT4 RCC improves prognostic accuracy Thompson RH et al. Cancer 2005; 104: 53-60

Reclassification of patients with pT3 and pT4 RCC improves prognostic accuracy Thompson RH et al. Cancer 2005; 104: 53-60

Proposal for reclassification of the TNM In patients with pT3-4 RCC Ficarra V et al. Eur Urol 2007; 51: pT3a new pT3b new pT4 new pT3a = perirenal fat invasion or renal vein involvement (V1) or IVC below diaphragm (V2) pT3b: V1 or V2 plus concomitant perirenal fat invasion pT4: adrenal gland or Gerota fascia invasion or IVC above diaphragm (V3) p < 0.001

Redefining pT3 Renal Cell Carcinoma In the modern Era Margulis V. et al. Cancer 2007; 109:

Ficarra V., et al. J Urol 2007; 178:

New staging system for pT3-4 RCC: a multicentric european study Ficarra V., et al. J Urol 2007; 178:

New staging system for pT3-4 RCC: a multicentric european study pT3a (new) pT3b (new) pT4 (new) p value< ,969 pT3-4 RCC 1,248 pT3-4 N0M0 RCC pT3a (new) pT3b (new) pT4 (new) p value< Ficarra V., et al. J Urol 2007; 178:

New staging system for pT3-4 RCC: a multicentric european study Ficarra V., et al. J Urol 2007; 178:

Renal sinus involvement in RCC Bonsib SM et al. Am J Surg Pathol 2000; 24:

Renal sinus involvement in RCC Thompson RH et al. J Urol 2005; 174:

Renal sinus involvement in RCC Margulis V et al. J Urol 2007; 178: patiens with pT3a RCC

Renal sinus involvement in pT3a

Prognostic relevance of tumour size in T3a Lam JS., Ficarra V, Patard JJ et al. Eur Urol 2007; 52: patients with pT3a Renal Cell Carcinoma

Lam JS., Ficarra V, Patard JJ et al. Eur Urol 2007; 52: N0-2 / M0-1 N0 / M0 Prognostic relevance of tumour size in T3a

Urinary collecting system (UCS) involvement is not included in the current TNM staging system. The UCS invasion in high stage tumours did not support a significantly worse prognosis, whereas in low stage tumours this prognostic factor can influence negatively the cancer specific survival rate However, in published series the UCS invasion did not result an independent prognostic factor At this time, this pathologic finding should not be considered in the new TNM staging system. Urinary collecting system invasion

Proposal of an improved prognostic Classification for pT3 Terrone C. et al. J Urol 2008; 180: 72-78

Proposal of an improved prognostic Classification for pT3 Terrone C. et al. J Urol 2008; 180: 72-78

New staging system for pT3-4 RCC: a multicentric european study Ficarra V., et al. J Urol 2007; 178: pT3a (new) pT3b (new) pT4 (new) p value< ,969 pT3-4 RCC 645 (524) 241 (223) 159 (156)

A new staging system for locally advanced (T3-4) RCC Ficarra V et al. Eur Urol 2007; 51:

Tumour Nodes and Metastases (TNM) Staging System Nx Regional Lymph nodes idem idem cannot be assessed cannot be assessed N1 Metastasis in 1 Lymph Metastasis to Metastasis to node  2 cm a single node a single node node  2 cm a single node a single node N2 Metastasis in 1 Lymph Metastasis in > Metastasis in > node > 2 cm but 2 cm but < 5 cm 1 Lymph node 1 Lymph node N3 Metastasis in 1 Lymph node > 5 cm node > 5 cm TNM, 1987 TNM, 1997 TNM, 2002

Reassessing the current TNM Lymph Node Staging for RCC Terrone C et al. Eur Urol 2006; 49:

Reassessing the current TNM Lymph Node Staging for RCC Terrone C et al. Eur Urol 2006; 49:

Reassessing the current TNM Lymph Node Staging for RCC Dimashkieh HH et al. J Urol 2006; 176:

Synchronous Distant Metastasis in patients with RCC

Cancer-specific survival according to TNM Staging System Karakiewicz P., Ficarra V. et al. Eur Urol 2007; 51: % 30% 27% (4.3%) 15% 8%

Other Independent Prognostic Factors Age at diagnosis, mode of presentation, performance status ECOG Pathological tumour size, Nuclear grading, Tumour necrosis, Sarcomatoid differentiation (?) Tumour histological type Molecular and genetic variables

Integrated prognostic systems

In real clinical practice, the mathematical models are today less used than the TNM especially for their - higher complexity - presence of more than one system - heterogeneity of the variables included Mathematical models to predict survival Ficarra V. et al. Lancet Oncol 2007; 8:

Adjuvant therapy in RCC: planned trials

The TNM system is a dynamic staging method which evolves and changes according to evidence coming for clinical data Confined RCC should be classified according to the new breakpoint of 5.5 cm and the different mode of presentation The correct classification of locally advanced RCC requires a better clustering of the various anatomical features characterizing the local extension of the primary tumour Conclusions

According to the results of the multivariate analyses, outcome predictive models including several clinical and pathological variables should be considered the best prognostic tools All the available nomograms and algorithms include older versions of the TNM staging system The integrated systems are today less used than the TNM classification Conclusions